# IDEXX Laboratories vs Medline: stocks compared

URL: https://funkfolio.com/compare/idxx-vs-mdln

> IDEXX Laboratories ($54.4B, P/E 47.2) and Medline ($49.6B, P/E 89.7) compared: size, valuation, margins, debt, cash and price change.

---

## IDEXX Laboratories vs Medline

IDEXX Laboratories (IDXX), health care, and Medline (MDLN), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

IDEXX Laboratories is worth $54.4B on the stock market and Medline $49.6B: IDEXX Laboratories is valued at 10% more. IDEXX Laboratories trades at 47.2 times earnings and Medline at 89.7; operating margins in their latest fiscal years were 31.6% and 7.78%. Over the past year IDEXX Laboratories's share price has moved +4.54% and Medline's -4.46%.

### Key facts

- **IDEXX Laboratories market value:** $54.4B
- **Medline market value:** $49.6B
- **IDEXX Laboratories P/E:** 47.2
- **Medline P/E:** 89.7
- **IDEXX Laboratories revenue:** $4.3B FY to 2025-12-31
- **Medline revenue:** $28.4B FY to 2025-12-31
- **Superinvestors holding both:** 1

Market values as of 18 Nov 2026, 05:11 UTC.

IDEXX Laboratories vs Medline: every measure side by side

| Measure | IDEXX Laboratories | Medline |
| --- | --- | --- |
| Sector | Health Care | Health Care |
| Country | United States | United States |
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size |  |  |
| Market cap | $54.4B higher | $49.6B lower |
| Revenue | $4.3B lower | $28.4B higher |
| Earnings | $1.1B lower | $1.2B higher |
| Employees | 11,000 lower | 45,000 higher |
| Total assets | $3.4B lower | $38.5B higher |
| Valuation |  |  |
| P/E | 47.2 lower | 89.7 higher |
| P/S | 12.6 higher | 1.7 lower |
| P/B | 29.1 higher | 2.8 lower |
| Dividend yield | 0.00% | 0.00% |
| Profitability |  |  |
| Operating margin | 31.6% higher | 7.78% lower |
| Balance sheet |  |  |
| Net assets | $1.6B lower | $10.7B higher |
| Total liabilities | $1.7B lower | $19.2B higher |
| Total debt | $450M lower | $12.6B higher |
| Cash on hand | $180.1M lower | $1.9B higher |
| Price change |  |  |
| Today | -1.49% higher | -3.80% lower |
| 1 year | +4.54% higher | -4.46% lower |

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

### Share price over one year

Each company's share price rebased to 100 on Dec 17, 2025, so the two lines start together. Price only: dividends are not included. Last: IDEXX Laboratories 99.2, Medline 91.9.

- IDEXX Laboratories (IDXX)
- Medline (MDLN)

IDEXX Laboratories and Medline share prices over one year, rebased to 100: IDEXX Laboratories ends at 99.2, Medline at 91.9.

**The chart as a table**

Month-end share prices rebased to 100

| Month end | IDXX | MDLN |
| --- | --- | --- |
| Dec 31, 2025 | 97.3 | 102.4 |
| Jan 30, 2026 | 96.4 | 107.8 |
| Feb 27, 2026 | 94.4 | 115.9 |
| Mar 31, 2026 | 80.8 | 108.5 |
| Apr 30, 2026 | 80.6 | 108.5 |
| May 29, 2026 | 81.0 | 89.2 |
| Jun 30, 2026 | 75.7 | 96.2 |
| Jul 31, 2026 | 80.4 | 95.8 |
| Aug 31, 2026 | 80.0 | 85.4 |
| Sep 30, 2026 | 75.1 | 84.6 |
| Oct 30, 2026 | 79.2 | 78.3 |
| Nov 17, 2026 | 99.2 | 91.9 |

### Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

#### Both (1)

- [Baillie Gifford team](https://funkfolio.com/gurus/baillie-gifford) 0.1% / 0.4%

#### IDEXX Laboratories only (9)

- [Terry Smith](https://funkfolio.com/gurus/terry-smith) 2.9%
- [Polen Capital team](https://funkfolio.com/gurus/polen-capital) 2.2%
- [Jensen team](https://funkfolio.com/gurus/jensen-investment) 1.8%
- [Ron Baron](https://funkfolio.com/gurus/ron-baron) 1.6%
- [Wallace Weitz](https://funkfolio.com/gurus/wallace-weitz) 1.3%
- [Brandon Haley](https://funkfolio.com/gurus/brandon-haley) 0.2%
- [Steve Cohen](https://funkfolio.com/gurus/steve-cohen) 0.2%
- [Mairs & Power team](https://funkfolio.com/gurus/mairs-and-power) &lt;0.1%
- [Bill Nygren](https://funkfolio.com/gurus/bill-nygren) &lt;0.1%

#### Medline only (5)

- [Stephen Mandel](https://funkfolio.com/gurus/stephen-mandel) 5.1%
- [John Armitage](https://funkfolio.com/gurus/john-armitage) 4.7%
- [Henry Ellenbogen](https://funkfolio.com/gurus/henry-ellenbogen) 1.0%
- [Andreas Halvorsen](https://funkfolio.com/gurus/andreas-halvorsen) 0.5%
- [George Soros](https://funkfolio.com/gurus/george-soros) 0.5%

Percentages are each holding's share of that investor's reported portfolio (under "Both": IDEXX Laboratories / Medline). [Who owns IDXX](https://funkfolio.com/stock/IDXX/superinvestors) · [Who owns MDLN](https://funkfolio.com/stock/MDLN/superinvestors)

### More on IDEXX Laboratories

- [IDEXX Laboratories (IDXX) stock page](https://funkfolio.com/stock/IDXX)
- [IDEXX Laboratories market cap](https://funkfolio.com/stock/IDXX/market-cap)
- [IDEXX Laboratories revenue](https://funkfolio.com/stock/IDXX/revenue)
- [IDEXX Laboratories P/E ratio](https://funkfolio.com/stock/IDXX/pe-ratio)
- [IDEXX Laboratories operating margin](https://funkfolio.com/stock/IDXX/operating-margin)
- [IDEXX Laboratories total debt](https://funkfolio.com/stock/IDXX/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### More on Medline

- [Medline (MDLN) stock page](https://funkfolio.com/stock/MDLN)
- [Medline market cap](https://funkfolio.com/stock/MDLN/market-cap)
- [Medline revenue](https://funkfolio.com/stock/MDLN/revenue)
- [Medline P/E ratio](https://funkfolio.com/stock/MDLN/pe-ratio)
- [Medline operating margin](https://funkfolio.com/stock/MDLN/operating-margin)
- [Medline total debt](https://funkfolio.com/stock/MDLN/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### Further comparisons

#### IDEXX Laboratories against its closest peers

- [IDEXX Laboratories vs Becton, Dickinson](https://funkfolio.com/compare/bdx-vs-idxx)
- [IDEXX Laboratories vs Edwards Lifesciences](https://funkfolio.com/compare/ew-vs-idxx)
- [IDEXX Laboratories vs argenx](https://funkfolio.com/compare/argx-vs-idxx)

#### Medline against its closest peers

- [Medline vs Humana](https://funkfolio.com/compare/hum-vs-mdln)
- [Medline vs Agilent Technologies](https://funkfolio.com/compare/a-vs-mdln)
- [Medline vs Becton, Dickinson](https://funkfolio.com/compare/bdx-vs-mdln)

### Learn

- [What market capitalization is and is not](https://funkfolio.com/learn/markets/market-capitalization)
- [P/E ratio explained](https://funkfolio.com/learn/stocks/pe-ratio)
- [Market cap vs enterprise value](https://funkfolio.com/learn/markets/market-cap-vs-enterprise-value)

### Questions and answers

**Which is bigger, IDEXX Laboratories or Medline?**

By market value, IDEXX Laboratories is the larger: $54.4B against $49.6B for Medline. By revenue in its latest fiscal year, Medline is the larger: $28.4B against $4.3B for IDEXX Laboratories.

**Which has the higher P/E ratio?**

Medline: 89.7, against 47.2 for IDEXX Laboratories. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

**Which has the higher operating margin?**

IDEXX Laboratories: 31.6%, against 7.78% for Medline. Operating margin is operating income as a share of revenue in the latest fiscal year.

**Which has the higher dividend yield?**

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

**Which has more debt?**

Medline: $12.6B, against $450M for IDEXX Laboratories. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

**Which superinvestors own both IDEXX Laboratories and Medline?**

In their latest 13F filings, Baillie Gifford team holds both.

### Cite this page

Funkfolio, “IDEXX Laboratories vs Medline”, data as of 18 November 2026. https://funkfolio.com/compare/idxx-vs-mdln

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.
